Onyx Pharmaceuticals (ONXX) +38.2% premarket after yesterday's FDA panel vote in favor of the...

|By:, SA News Editor

Onyx Pharmaceuticals (ONXX) +38.2% premarket after yesterday's FDA panel vote in favor of the company's Kyprolis drug for multiple myeloma. The final FDA approval decision is expected July 27. Shares are upgraded to Outperform from Neutral at Baird, initiated with a Buy at Deutsche Bank, and upgraded to Buy at Brean Murray.